The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

BACKGROUND: Activation of the epidermal growth factor receptor (EGFR) triggers downstream signaling pathways that regulate many cellular processes involved in tumour survival and growth. Gefitinib ('Iressa') is an orally active tyrosine kinase inhibitor (TKI) targeted to the ATP-binding do...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight, Louise A, Di Nicolantonio, Federica, Whitehouse, Pauline, Mercer, Stuart, Sharma, Sanjay, Glaysher, Sharon, Johnson, Penny, Cree, Ian A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC535559/
https://www.ncbi.nlm.nih.gov/pubmed/15560844
http://dx.doi.org/10.1186/1471-2407-4-83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC535559/
https://www.ncbi.nlm.nih.gov/pubmed/15560844
http://dx.doi.org/10.1186/1471-2407-4-83

Ejemplares similares